Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
– Expands Sobi’s pipeline with a highly differentiated new Phase 3 asset in Gout– Acquisition
Arthrosi Secures $153 Million in Series E Financing to Complete Pivotal Development of Pozdeutinurad for the Treatment of Gout and Tophaceous Gout
Enrollment complete in the replicate REDUCE 1 and REDUCE 2 Phase 3 studies with pivotal data expected in Q2 2026 SAN
Arthrosi Therapeutics Achieves Full Enrollment of the Second Pivotal Phase 3 Trial of Pozdeutinurad (AR882) in Patients with Gout, Including Those with Tophaceous Gout
— Enrollment completed well ahead of schedule; both Phase 3 trials now fully enrolled with data expected
About Us
Arthrosi Therapeutics is a clinical-stage biotech company focused on the development of therapy for gout and chronic kidney disease. Its proprietary drug candidate, AR882, demonstrated unprecedent sustained urate lowering in gout patients and showed potential to treat a variety of renal impaired patients suffering from gout and tophaceous gout..
Arthrosi strives to…
- Create a people-centered environment — you are at the center of everything we do and every decision we make.
- Be your partner in health — we work to bring a better quality of life to our patients.
US gout patients
with flares
with tophi
chronic refractory gout patients
A large percentage of the 9 million patients living with gout are undertreated, relying on short-term or sub-optimal treatments that don’t meet their needs. Our mission is to eliminate the pain of gout with a new era of gout treatment that provides a true solution to reduce flare and tophi.
Litain Yeh
Co-Founder and CEO
